


Data Sheet

Product Name:	Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA)
Cat. No.:	CS-0062738
CAS No.:	199807-33-5
Molecular Formula:	C ₂₈ H ₃₉ F ₃ N ₈ O ₉
Molecular Weight:	688.65
Target:	Integrin
Pathway:	Cytoskeleton
Solubility:	10 mM in DMSO



BIOLOGICAL ACTIVITY:

Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of **integrin $\alpha v \beta 3$** , with antitumor activity. IC₅₀ & Target: $\alpha v \beta 3$ ^[1] **In Vitro:** Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin $\alpha v \beta 3$. Cyclo(Arg-Gly-Asp-D-Phe-Val) [c(RGDfV); 35 nM] induces disruption of leukemia cell migration and adhesion to leukemia osteoblasts in the 3D and 2D culture systems, affects the leukemia cell cycle and induces apoptosis in leukemia cells^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: ^[1]The osteoblasts are cultured in RPMI 1640 medium for 2 days. MV4-11 cells (1.8×10^5 cells/mL in the 2D culture system and 1×10^6 cells/mL in the 3D culture system) are co-cultured with leukemia osteoblasts in RPMI 1640 medium. The experiments used two groups: The experimental group received c(RGDfV) (35 nmol/mL) and the control group received an equal volume of phosphate-buffered saline (PBS) only^[1].

References:

[1]. Shen ZH, et al. Targeting of the leukemia microenvironment by c(RGDfV) overcomes the resistance to chemotherapy in acute myeloid leukemia in biomimetic polystyrene scaffolds. *Oncol Lett.* 2016 Nov;12(5):3278-3284.

CAIndexNames:

Cyclo(L-arginylglycyl-L- α -aspartyl-D-phenylalanyl-L-valyl),2,2,2-trifluoroacetate (1:1)

SMILES:

O=C([C@@H](NC(CNC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC1=O)=O)=O)CC(O)=O)N[C@@H]1CC2=CC=CC=C2.FC(C(O)=O)(F)F

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA